Main menu

Noninvasive Prenatal Testing by Nanopore Sequencing of Maternal Plasma DNA: Feasibility Assessment

Noninvasive Prenatal Testing by Nanopore Sequencing of Maternal Plasma DNA: Feasibility Assessment
Return to ResourcesRead the full text
  • Published on: January 29 2015
  • Source: Clinical Chemistry

Noninvasive prenatal testing (NIPT) by maternal plasma DNA sequencing is now clinically available for screening fetal chromosomal aneuploidies; these tests have close to 99% sensitivity.. [subscription required, please click here for the article or here for the GenomeWeb article]

Authors: Suk Hang Cheng, Peiyong Jiang, Kun Sun, Yvonne K.Y. Cheng, K.C. Allen Chan, Tak Y. Leung, Rossa W.K. Chiu, Y.M. Dennis Lo

入门指南

购买 MinION 启动包 Nanopore 商城 测序服务提供商 全球代理商

联系我们

知识产权 Cookie 政策 企业报告 隐私政策 条件条款 前瞻性陈述

关于 Oxford Nanopore

联系我们 领导团队 媒体资源和联系方式 投资者 在 Oxford Nanopore 工作 BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust

沪ICP备20017565号 © 2008 - 2023 Oxford Nanopore Technologies plc。版权所有。注册办公室：Gosling Building, Edmund Halley Road, Oxford Science Park, OX4 4DQ, UK（英国）注册号 05386273 增值税号 336942382。Oxford Nanopore Technologies、风轮图标、EPI2ME、Flongle、GridION、Metrichor、MinION、MinIT、MinKNOW、Plongle、 PromethION、SmidgION、Ubik 和 VolTRAX 是 Oxford Nanopore Technologies plc 在 不同国家的注册商标。Oxford Nanopore Technologies 产品并非旨在用于健康评估或 诊断、治疗、缓解、治愈或预防任何疾病或状况。

Chinese flag